Conference: Non-Coding RNAs and Epigenetics in Cancer

2nd International Symposium on Frontiers in Molecular Science

Non-Coding RNAs & Epigenetics in Cancer

 

2nd International Symposium on Frontiers in Molecular Science Non-Coding RNAs and Epigenetics in Cancer logo

21–23 June 2017

Biocenter, University of Basel, Basel, Switzerland

Announcement: Final Deadline for Early Registration Fees 31 March 2017

An international scientific conference organized by the MDPI journals International Journal of Molecular Sciences and Non-Coding RNA

One of the most unexpected and fascinating discoveries in oncology over the past decade has been the interplay between abnormalities in protein-coding genes and non-coding RNAs (ncRNAs), which are causally involved in cancer initiation, progression, and dissemination. Although, to date, the most studied non-coding RNAs (ncRNAs) are miRNAs, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognized. At the conference, entitled “Non-Coding RNAs and Epigenetics in Cancer”, leaders in the field will present the roles of miRNAs and lncRNAs in cancer, with a focus on the recently identified novel mechanisms of action, and discuss the current strategies in designing ncRNA-targeting therapeutics, as well as the associated challenges. We hope to see you all, young in spirit and mind, in the new Eldorado of Science topics in biomedical sciences!

The Non-Coding RNAs and Epigenetics in Cancer will be held in Basel, Switzerland, from 21st to 23rd of June 2017. It will comprise five plenary sessions to highlight the most exciting developments and the latest breakthroughs in oncology.

If you are interested in participating in this conference, and in presenting a poster, or in being selected for a short talk, please register and get in touch with the conference secretariat. The program of the conference is being assembled and will be fully available by March 2017.

For more details and to register: http://sciforum.net/conference/ncRNA-Cancer

Subscribe to the miRNA blog

Thank you for subscribing.

Something went wrong.

Related Posts

Add Comment